Payment overview · 2025
General Payments
$212.80
13 reported records · 5 companies
Healthcare provider profile · identity verified
Ritesh Kalra, M.D.
Allopathic & Osteopathic Physicians|General Practice · FAIR LAWN, NJ · NPI 1043436348
Verified facts
What the public records show
CMS Open Payments records show Ritesh Kalra, M.D. received $212.80 in general payments during 2025 across 13 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 36.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess, Pifeltro, Relistor, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Linzess by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Biktarvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Trelegy Ellipta by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PIFELTRO as an associated drug or biological on 7921 records involving 2912 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Pifeltro by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RELISTOR as an associated drug or biological on 23206 records involving 6246 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Relistor by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $77.17 | 36.3% | 5 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $54.11 | 25.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.94 | 21.6% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.00 | 8.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.58 | 7.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $212.80 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $77.17 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $45.94 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $45.94 | 3 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 131 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 84 | exact normalized | Medicare Part D |
| PIFELTRO pifeltro |
2025 | Pifeltro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RELISTOR relistor |
2025 | Relistor | 2024 | 92 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 141 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
131 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
84 | 16 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
141 | 29 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PIFELTRO open payments reported associated product |
CMS Open Payments — General Payments 7921 supporting records · 2912 recipient NPIs · example record 1237992198 |
Pifeltro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | RELISTOR open payments reported associated product |
CMS Open Payments — General Payments 23206 supporting records · 6246 recipient NPIs · example record 1231775437 |
Relistor · 2024 Exact normalized brand match · 1 Part D row |
92 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Promethazine Hcl | Promethazine Hcl | 1136 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 755 | 83 |
| Atrovent Hfa | Ipratropium Bromide | 499 | 77 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 455 | 67 |
| Albuterol Sulfate | Albuterol Sulfate | 419 | 51 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 384 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 300 | 64 |
| Mupirocin | Mupirocin Calcium | 281 | 44 |
| Ciclopirox | Ciclopirox Olamine | 280 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 254 | 38 |
| Lidocaine | Lidocaine | 223 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 196 | 37 |
| Lubiprostone | Lubiprostone | 192 | 39 |
| Azithromycin | Azithromycin | 150 | 29 |
| Varenicline Tartrate | Varenicline Tartrate | 146 | 28 |
| Atorvastatin Calcium | Atorvastatin Calcium | 144 | 33 |
| Endocet | Oxycodone Hcl/Acetaminophen | 144 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 141 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 134 | 19 |
| Metformin Hcl | Metformin Hcl | 134 | 16 |
| Creon | Lipase/Protease/Amylase | 131 | 23 |
| Azelastine Hcl | Azelastine Hcl | 130 | 14 |
| Epinephrine | Epinephrine | 130 | 22 |
| Omeprazole | Omeprazole | 130 | 20 |
| Ibuprofen | Ibuprofen | 129 | 33 |
| Halobetasol Propionate | Halobetasol Propionate | 125 | 14 |
| Zileuton Er | Zileuton | 123 | 44 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 122 | 28 |
| Mometasone Furoate | Mometasone Furoate | 121 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 118 | 18 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 117 | 32 |
| Ammonium Lactate | Ammonium Lactate | 116 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 109 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 12 |
| Naloxone Hcl | Naloxone Hcl | 99 | 37 |
| Vascepa | Icosapent Ethyl | 96 | 32 |
| Naftifine Hcl | Naftifine Hcl | 95 | 16 |
| Incruse Ellipta | Umeclidinium Bromide | 92 | 17 |
| Montelukast Sodium | Montelukast Sodium | 92 | 25 |
| Relistor | Methylnaltrexone Bromide | 92 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 35 |
| Hydrocortisone | Hydrocortisone | 88 | 16 |
| Ketoconazole | Ketoconazole | 87 | 19 |
| Linzess | Linaclotide | 84 | 16 |
| Famotidine | Famotidine | 76 | 11 |
| Prednisone | Prednisone | 69 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 16 |
| Clotrimazole | Clotrimazole | 67 | suppressed |
| Acyclovir | Acyclovir | 66 | 11 |
| Colesevelam Hcl | Colesevelam Hcl | 56 | suppressed |
| Ozempic | Semaglutide | 55 | suppressed |
| Crotan | Crotamiton | 53 | 27 |
| Arnuity Ellipta | Fluticasone Furoate | 52 | 17 |
| Alprazolam | Alprazolam | 51 | suppressed |
| Atovaquone | Atovaquone | 51 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | suppressed |
| Celecoxib | Celecoxib | 50 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 50 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 49 | 15 |
| Movantik | Naloxegol Oxalate | 48 | suppressed |
| Restasis | Cyclosporine | 48 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 47 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | suppressed |
| Lisinopril | Lisinopril | 46 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 46 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 42 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 41 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 41 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 41 | 25 |
| Naproxen | Naproxen | 39 | suppressed |
| Calcipotriene | Calcipotriene | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 36 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 36 | 19 |
| Furosemide | Furosemide | 36 | suppressed |
| Lactulose | Lactulose | 36 | 11 |
| Meloxicam | Meloxicam | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | suppressed |
| Butalbital-Acetaminophen | Butalbital/Acetaminophen | 34 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 34 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 32 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 31 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Darunavir | Darunavir | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Tivicay | Dolutegravir Sodium | 27 | suppressed |
| Ciclopirox | Ciclopirox | 26 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Mesalamine | Mesalamine | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Clemastine Fumarate | Clemastine Fumarate | 23 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Fluocinonide | Fluocinonide | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Losartan Potassium | Losartan Potassium | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Pifeltro | Doravirine | 16 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 16 | suppressed |
| Zafirlukast | Zafirlukast | 16 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 15 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Gabapentin | Gabapentin | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 14 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Fluocinonide-E | Fluocinonide/Emollient Base | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Ultiguard Safepack-Pen Needle | Pen Needle, Diabetic,disp Unit | 13 | suppressed |
| Amcinonide | Amcinonide | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Xiidra | Lifitegrast | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $212.80 · 13 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | CREON, LINZESS, PIFELTRO, RELISTOR, TRELEGY ELLIPTA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error